| |
|
Q. |
Name of Institution: Newark Beth Israel Medical Center, New Jersey
Total number of patients per year: 1,000
How would you best describe your current practice setting and responsibilities within your institution?
Response by
Marc Cohen, MD |
|
A. |
I am a full-time salaried employee of the Medical Center. I see outpatients in an office setting within the hospital. I perform diagnostic and interventional cardiac procedures at the hospital. I teach and oversee the General Cardiology Fellowship and contribute substantially to the Interventional Cardiology Fellowship training programs at the Medical Center. Lastly, I oversee the Division of Cardiology, which includes approximately 10 other salaried faculty members.
Response date: August 2008
|
|
|
Q. |
What do you do as a researcher and how do you balance your many research and teaching responsibilities?
Response by
Marc Cohen, MD |
|
A. |
My main research interests are clinical antithrombotic therapy trials and interventional trials, dating back to 1981. The first interventional trial I participated in, with the support and supervision of Dr. Peter Rentrop, which incidentally also involved antithrombotic therapy (intracoronary streptokinase), was the National Institutes of Health–sponsored randomized clinical trial of nonsurgical reperfusion in acute myocardial infarction in 1982. The first antithrombotic therapy trial I undertook, with the support and supervision of Dr. Valentin Fuster, the Chief of Cardiology, was the ATACS trial, comparing aspirin and warfarin versus aspirin alone in unstable angina in 1989. A lot of the non–patient-related work for these projects was done “after hours and on weekends.” By getting the fellows involved in many of the clinical trials I lead or am involved with, I can overlap my teaching responsibilities with my research interests.
Response date: August 2008
|
|
|
Q. |
What is your current primary area of research interest as it relates to platelet function and novel antiplatelet approaches?
Response by
Marc Cohen, MD |
|
A. |
Most recently, we were involved in the TRITON trial. I still believe that potent antiplatelet therapy is a key way to reduce periprocedural ischemic events in both acute as well as elective percutaneous coronary intervention.
Response date: August 2008
|
|
|
Q. |
How is clinical research conducted in your lab?
Response by
Marc Cohen, MD |
|
A. |
At Newark Beth Israel Medical Center in New Jersey, we have a clinical research group composed of 4 full-time registered nurses, a nurse’s assistant, and an administrator. These individuals divide the work of approximately 12 ongoing clinical trials.
Response date: August 2008
|
|
|
Q. |
What is currently the most interesting ongoing study in which you are participating as an investigator?
Response by
Marc Cohen, MD |
|
A. |
The ATOLL study, comparing simple intravenous bolus-only low-molecular-weight heparin versus traditional intravenous bolus plus infusion of unfractionated heparin in ST-segment elevation myocardial infarction (STEMI). If found to be safe and effective, the bolus-only strategy should greatly streamline rapid care of the STEMI patient being rushed to primary PCI.
Response date: August 2008
|
|
|